Personalized treatment through a Dry Powder inhaler device (DPI), adjustable to Chronic Obstructive Pulmonary Disease (COPD) patient′s respiratory profile

被引：0

作者：

Zarogoulidis, Konstantinos ^{[1
]}

Michailidis, Nikolaos ^{[1
]}

Siopi, Dimitra ^{[2
]}

Tsiouda, Theodora ^{[3
]}

Theodoridou, Anatoli ^{[3
]}

Koltsida, Ourania ^{[4
]}

Rapti, Aggeliki ^{[4
]}

Petridis, Dimitrios ^{[5
]}

Porpodis, Konstantinos ^{[1
]}

Babalis, Georgios ^{[2
]}

Petanidis, Savvas ^{[1
]}

Chloros, Diamantis ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Thessaloniki, Greece

[2] G Papanikolaou Gen Hosp, Thessaloniki, Greece

[3] Theageneio Anticanc Hosp, Thessaloniki, Greece

[4] Sotiria Gen Hosp, Athens, Greece

[5] Int Hellenic Univ, Thessaloniki, Greece

来源：

EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷

关键词：

D O I：

10.1183/13993003.congress-2023.PA545

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2

共 50 条

[31] INHALATION CHARACTERISTICS WITH SPIROMAX® AND TURBUHALER® DRY POWDER INHALERS (DPI) IN HEALTHY ADULTS AND PATIENTS WITH ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): BEFORE AND AFTER ENHANCED TRAINING
Chrystyn, H.
Azouz, W.
Chetcuti, P.
Hosker, H.
Saralaya, D.
THORAX, 2013, 68 : A178 - A179
[32] An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease
Hogan, TJ
Geddes, R
Gonzalez, ER
CLINICAL THERAPEUTICS, 2003, 25 (01) : 285 - 297
[33] ECONOMIC EVALUATION OF TIOTROPIUM/OLODATEROL ADMINISTRATED THROUGH THE RESPIMAT INHALER AS MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN POLAND
Pawlik, M.
Karwala, P.
Zyla, A.
Parkitny, M.
Walczak, J.
Pieniazek, I
Augustynska, J.
Zawodnik, A.
VALUE IN HEALTH, 2016, 19 (07) : A554 - A554
[34] Aclidinium bromide/formoterol fumarate dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease in the EU
Lyseng-Williamson K.A.
Drugs & Therapy Perspectives, 2015, 31 (6) : 183 - 189
[35] PREFERENCES FOR DRY POWDER INHALER ATTRIBUTES AMONG PATIENTS WITH ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM FIVE EUROPEAN COUNTRIES
Hawken, N. A.
Amri, I
Neine, Elmoctar M.
Aballea, S.
Torvinen, S.
Plich, A.
VALUE IN HEALTH, 2015, 18 (07) : A364 - A364
[36] Quantifying The Severity Of Respiratory Symptoms Of Chronic Obstructive Pulmonary Disease (COPD): Reliability And Validity Of A Patient Diary
Sexton, C. C.
Leidy, N. K.
Notte, S. M.
Jones, P.
Monz, B. U.
Nelsen, L.
Ramachandran, S.
Sethi, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[37] IDENTIFICATION OF DRY POWDER INHALER ATTRIBUTES, AND THEIR RELATIVE IMPORTANCE TO ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS, TO INFORM A DISCRETE CHOICE EXPERIMENT
Hawken, N. A.
Aballea, A. S.
Torvinen, S.
Plich, A.
VALUE IN HEALTH, 2014, 17 (07) : A600 - A600
[38] Personalized Treatment Strategies and Long- Term Prognosis Analysis for Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lin, Huijin
RESEARCH IN NURSING & HEALTH, 2025, 48
[39] Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease
Leaker, Brian R.
Singh, Dave
Nicholson, Grant C.
Hezelova, Blanka
Goodin, Thomas
Ozol-Godfrey, Ayca
Galluppi, Gerald
Barnes, Peter J.
RESPIRATORY RESEARCH, 2019, 20 (1)
[40] Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease
Siler, Thomas
Jain, Renu
Collison, Kathryn
Sharma, Raj I.
Sutton, Laura
Rees, Jamie
Bernstein, David
PLOS ONE, 2022, 17 (08):

← 1 2 3 4 5 →